141 research outputs found

    Frost resistance of grapevine cultivars of different origin

    Get PDF
    The tests of resistance to low temperature which included a large number of grapevine cultivars showed that the cultivars bore sign of their ecological-geographical and genetic origins with respect to the resistance to low temperature. The tests, conducted over several years, consisted of exposing cuttings of annual shoots to low temperature in a cold chamber. The tests were repeated three times each winter, following the uniform method and time, in order to be able to distinguish relative differences in the degree of resistance between the cultivars tested. Most cultivars from Western Europe (occidentalis NEGR., gallica NEM.) had a high degree of resistance to low temperature. They tended to reach the peak of the resistance in mid winter. The cultivars from the continental part of the Balkans (pontica NEGR, balcanica NEGR.) were unanimously sensitive to low temperature. The cultivars from the warm Mediterranean climate of Southern Europe (pontica NEGR., balcanica NEGR and occidentalis NEGR, iberica NEM.) were still more sensitive than the cultivars in the previously mentioned group. The wine cultivars developed from interspecific crosses of European grapevines and American species exhibited a high degree of resistance in the middle and at the end of winter while the hybrids vinifera x amurensis were highly resistant at the beginning and in the middle of winter. Both groups can be used as donors of resistance to low temperature in programs of breeding cold hardy grapevine cultivars. The tested table cultivars were found to be sensitive to low temperature, with the exception of the well-known cultivars Muscat Hamburg and Chasselas and the new cultivars Strugurash and Moldova

    The importance of clonal selection of grapevine and the role of selected clones in production of healthy propagating stocks

    Get PDF
    Genetical alterations and phytosanitary status promote the variability and modify the appearance of vine. Old vine varieties in old vineyards are highly variable and well adapted to selection. Clonal selektion is based on a visual performance: valuable individuals (clones) are picked out according to visible symptoms or characters. The genetical stability of clones is proved by testing the vegetatively propagated progenies on the basis of morphological and molekular (SSR, AFLP, SMPL, RAPD) markes. Authors take great care of the visual phytosanitary selection as part of the clonal selection being the oreliminary step to develop pathogen-free propagation stocks. In Serbia (Vojvodina) the selection breeding has been carried on for several decades resulted in comparative clone trials with home and imported clones of Welsch Riesling, Chardonnay, Pinot gris, White Riesling. Among the clones of home selection SK.54 Welsch Riesling clone is the most valuable. Its clearing from pathogene is being carried on in an interregional IPA programme (HUSRB/0901/214/123) in Kecskemét. In Kecskemét, the centre of the Hungarian Danube vine region 5 vine clones have been registered (Cegléd szépe K.73, Irsai Olivér K.11, Kövidinka K.8, Hårslevelû K.9, Pannónia kincse K.56). Besides them 18 virus-tested clones have also been qualified.Works aiming at their complete exemption are going on in order to obtain clones free of propagation wood-borne diseases

    The importance of clonal selection of grapevine and the role of selected clones in production of healthy propagating stocks

    Get PDF
    Genetical alterations and phytosanitary status promote the variability and modify the appearance of vine. Old vine varieties in oldvineyards are highly variable and well adapted to selection. Clonal selektion is based on a visual performance: valuable individuals (clones)are picked out according to visible symptoms or characters. The genetical stability of clones is proved by testing the vegetatively propagatedprogenies on the basis of morphological and molekular (SSR, AFLP, SMPL, RAPD) markes.Authors take great care of the visual phytosanitary selection as part of the clonal selection being the preliminary step to develop pathogen-freepropagation stocks.In Serbia (Vojvodina) the selection breeding has been carried on for several decades resulted in comparative clone trials with home andimported clones of Welsch Riesling, Chardonnay, Pinot gris, White Riesling. Among the clones of home selection SK.54 Welsch Rieslingclone is the most valuable. Its clearing from pathogene is being carried on in an interregional IPA programme (HUSRB/0901/214/123) inKecskemét.In Kecskemét, the centre of the Hungarian Danube vine region 5 vine clones have been registered (Cegléd szépe K.73, Irsai Olivér K.11,Kövidinka K.8, Hårslevelû K.9, Pannónia kincse K.56). Besides them 18 virus-tested clones have also been qualified.Works aiming at theircomplete exemption are going on in order to obtain clones free of propagation wood-borne diseases

    Binding of SGTA to Rpn13 selectively modulates protein quality control

    Get PDF
    YesRpn13 is an intrinsic ubiquitin receptor of the 26S proteasome regulatory subunit that facilitates substrate capture prior to degradation. Here we show that the C-terminal region of Rpn13 binds to the tetratricopeptide repeat (TPR) domain of SGTA, a cytosolic factor implicated in the quality control of mislocalised membrane proteins (MLPs). The overexpression of SGTA results in a substantial increase in steady-state MLP levels, consistent with an effect on proteasomal degradation. However, this effect is strongly dependent upon the interaction of SGTA with the proteasomal component Rpn13. Hence, overexpression of the SGTA-binding region of Rpn13 or point mutations within the SGTA TPR domain both inhibit SGTA binding to the proteasome and substantially reduce MLP levels. These findings suggest that SGTA can regulate the access of MLPs to the proteolytic core of the proteasome, implying that a protein quality control cycle that involves SGTA and the BAG6 complex can operate at the 19S regulatory particle. We speculate that the binding of SGTA to Rpn13 enables specific polypeptides to escape proteasomal degradation and/or selectively modulates substrate degradation.BBSRC [grant number: BB/L006510/1] and the Wellcome Trust [grant number: 092107/Z/10/Z]. K.K. was supported by the UPStream network [EU, FP7, ITN project 290257

    Governance tools for board members : adapting strategy maps and balanced scorecards for directorial action

    Get PDF
    The accountability of members of the board of directors of publicly traded companies has increased over years. Corresponding to these developments, there has been an inadequate advancement of tools and frameworks to help directorial functioning. This paper provides an argument for design of the Balanced Scorecard and Strategy Maps made available to the directors as a means of influencing, monitoring, controlling and assisting managerial action. This paper examines how the Balanced Scorecard and Strategy Maps could be modified and used for this purpose. The paper suggests incorporating Balanced Scorecards in the Internal Process perspective, ‘internal’ implying here not just ‘internal to the firm’, but also ‘internal to the inter-organizational system’. We recommend that other such factors be introduced separately under a new ‘perspective’ depending upon what the board wants to emphasize without creating any unwieldy proliferation of measures. Tracking the Strategy Map over time by the board of directors is a way for the board to take responsibility for the firm’s performance. The paper makes a distinction between action variables and monitoring variables. Monitoring variables are further divided on the basis of two considerations: a) whether results have been met or not and b) whether causative factors have met the expected levels of performance or not. Based on directorial responsibilities and accountability, we take another look at how the variables could be specified more completely and accurately with directorial recommendations for executives

    Corrigendum to "European contribution to the study of ROS:A summary of the findings and prospects for the future from the COST action BM1203 (EU-ROS)" [Redox Biol. 13 (2017) 94-162]

    Get PDF
    The European Cooperation in Science and Technology (COST) provides an ideal framework to establish multi-disciplinary research networks. COST Action BM1203 (EU-ROS) represents a consortium of researchers from different disciplines who are dedicated to providing new insights and tools for better understanding redox biology and medicine and, in the long run, to finding new therapeutic strategies to target dysregulated redox processes in various diseases. This report highlights the major achievements of EU-ROS as well as research updates and new perspectives arising from its members. The EU-ROS consortium comprised more than 140 active members who worked together for four years on the topics briefly described below. The formation of reactive oxygen and nitrogen species (RONS) is an established hallmark of our aerobic environment and metabolism but RONS also act as messengers via redox regulation of essential cellular processes. The fact that many diseases have been found to be associated with oxidative stress established the theory of oxidative stress as a trigger of diseases that can be corrected by antioxidant therapy. However, while experimental studies support this thesis, clinical studies still generate controversial results, due to complex pathophysiology of oxidative stress in humans. For future improvement of antioxidant therapy and better understanding of redox-associated disease progression detailed knowledge on the sources and targets of RONS formation and discrimination of their detrimental or beneficial roles is required. In order to advance this important area of biology and medicine, highly synergistic approaches combining a variety of diverse and contrasting disciplines are needed

    Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

    Get PDF
    Background: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. Methods: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1ÎČ, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. RESULTS: At 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 37 percentage points greater in the 150-mg group, and 41 percentage points greater in the 300-mg group than in the placebo group. Canakinumab did not reduce lipid levels from baseline. At a median follow-up of 3.7 years, the incidence rate for the primary end point was 4.50 events per 100 person-years in the placebo group, 4.11 events per 100 person-years in the 50-mg group, 3.86 events per 100 person-years in the 150-mg group, and 3.90 events per 100 person-years in the 300-mg group. The hazard ratios as compared with placebo were as follows: in the 50-mg group, 0.93 (95% confidence interval [CI], 0.80 to 1.07; P = 0.30); in the 150-mg group, 0.85 (95% CI, 0.74 to 0.98; P = 0.021); and in the 300-mg group, 0.86 (95% CI, 0.75 to 0.99; P = 0.031). The 150-mg dose, but not the other doses, met the prespecified multiplicity-adjusted threshold for statistical significance for the primary end point and the secondary end point that additionally included hospitalization for unstable angina that led to urgent revascularization (hazard ratio vs. placebo, 0.83; 95% CI, 0.73 to 0.95; P = 0.005). Canakinumab was associated with a higher incidence of fatal infection than was placebo. There was no significant difference in all-cause mortality (hazard ratio for all canakinumab doses vs. placebo, 0.94; 95% CI, 0.83 to 1.06; P = 0.31). Conclusions: Antiinflammatory therapy targeting the interleukin-1ÎČ innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. (Funded by Novartis; CANTOS ClinicalTrials.gov number, NCT01327846.

    The motivations for the adoption of management innovation by local governments and its performance effects

    Get PDF
    This article analyses the economic, political and institutional antecedents and performance effects of the adoption of shared Senior Management Teams (SMTs) – a management innovation (MI) that occurs when a team of senior managers oversees two or more public organizations. Findings from statistical analysis of 201 English local governments and interviews with organizational leaders reveal that shared SMTs are adopted to develop organisational capacity in resource‐challenged, politically risk‐averse governments, and in response to coercive and mimetic institutional pressures. Importantly, sharing SMTs may reduce rather than enhance efficiency and effectiveness due to redundancy costs and the political transaction costs associated with diverting resources away from a high‐performing partner to support their lower‐performing counterpart

    The Pivitol Role of Perceived Discretion in Top Teams Setting a Research Agenda.

    No full text
    The strategic leadership research stream characterisd by the predominantly instrumental upper-echelon research stream has provided extensive support for the strategic choice school of thought. In recent years it has been ctiticised for failing to develop from an exploration of whether relationships exist between managers background characteristics and their strategic choices and firm performances to an exploration of how managers characteristics influence outcomes. This paper provides a way forward and identifies perceived discretion as a pivotal concept in the exploration of the black box of demographic research and clearly separates the concepts of perceived, situational and enacted discretion. A broad conceptual framework, built on rather than replacing precious frameworks, is presented and future research is indicated. The concept of the discretion funnel is also introduced
    • 

    corecore